Please assess the completion status of the following clinical trial:

Trial Title: DE-117 Spectrum 5 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Primary Open-Angle Glaucoma or Ocular Hypertension in one or both eyes.~* Provide signed written informed consent.~* Diagnosis of POAG or OHT in both eyes.~* Qualifying corrected visual acuity in each eye.~* Qualifying central corneal thickness in each eye.~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes after latanoprost Run-in Period.~* Qualifying Anterior chamber angle.~* Qualifying IOP measurement at 3 time-points during latanoprost Run-in Period.~Exclusion Criteria:~* Patients who cannot safely discontinue use of Ocular Hypotensive Medications during Washout.~* Patients with prior exposure to DE-117.~* History of ocular surgery specifically intended to lower IOP~* Advanced glaucoma in either eye.~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry.~* Any ocular surgery or ocular laser treatment within 180 days prior to Visit 1 (Screening) and throughout the study in either eye.~* Females who are pregnant, nursing, or planning a pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 Ophthalmic Solution 0.002% (Type: EXPERIMENTAL): Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).